

Applicants: Walter P. Carney et al.
Serial No.: 08/488,180
Filed: June 7, 1995
Page 2

B1
concl'd 18
~~17~~ 17. (amended) Hybridoma cell line, designated NB-3, having ATCC accession number HB 10205.--

~~18~~ 18. (amended) Hybridoma cell line, designated TA-1, having ATCC accession number HB 10206.--

19
~~19~~ 19. (new) Monoclonal antibody produced by the hybridoma cell line of claim ~~18~~ *16*.--

20
~~20~~ 20. (new) Monoclonal antibody produced by the hybridoma cell line of claim ~~19~~ *17*.--

21
~~21~~ 21. (new) Monoclonal antibody produced by the hybridoma cell line of claim ~~20~~ *18*.--

22
~~22~~ 22. (new) An immunoreactive fragment of the monoclonal antibody of claim ~~21~~ *19*.--

23
~~23~~ 23. (new) An immunoreactive fragment of the monoclonal antibody of claim ~~22~~ *20*.--

24
~~24~~ 24. (new) An immunoreactive fragment of the monoclonal antibody of claim ~~23~~ *21*.--

REMARKS

Claims 13-18 are pending in the subject application. Applicants have amended claims 16-18 to more particularly point out the claimed invention. Applicants have added claims 19-24 to more fully claim the subject matter presently claimed. Support for "OD-3", "TA-3" and "NB-1" may be found in the subject specification on page 9, lines 1-19 and in U.S. Serial No. 07/182,501, filed April 18, 1988 (a parent application of the subject application) on page

52

B